<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027598</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI LUN 200</org_study_id>
    <nct_id>NCT01027598</nct_id>
  </id_info>
  <brief_title>Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, placebo-controlled, Phase II trial will compare the combination of erlotinib
      with pazopanib (providing concurrent EGFR and VEGFR inhibition) with erlotinib alone in the
      second- or third-line treatment of patients with advanced NSCLC. This study will be conducted
      though the Sarah Cannon Research Consortium, a community-based clinical trial network.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Erlotinib is the current treatment standard for second- or third-line therapy of advanced
      NSCLC. Since angiogenesis inhibitors have also shown activity in NSCLC, the simultaneous
      inhibition of the EGFR and VEGF pathway may improve the efficacy of therapy. In a recently
      reported Phase III trial (Hainsworth et al. 2008), the combination of bevacizumab and
      erlotinib improved the Progression- Free-Survival (PFS) vs. erlotinib alone when given as
      second-line therapy in NSCLC (3.4 months vs. 1.7 months, respectively; HR 0.63). Pazopanib
      also inhibits the angiogenesis pathway, and may have advantages over bevacizumab including:
      (1) inhibition of other potentially important targets, including PDGFR; and (2) more
      convenient oral administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>14 months</time_frame>
    <description>The length of time, in months, that patients were alive from first date of protocol treatment until worsening of disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>18 months</time_frame>
    <description>The length of time, in months, that patients were alive from first date of protocol treatment until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>18 Months</time_frame>
    <description>The percentage of patients having an objective benefit from treatment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Erlotinib + Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib: 150 mg orally daily
Pazopanib: 600 mg orally daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Erlotinib: 150 mg orally daily
Placebo: orally daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Pazopanib: 600 mg orally daily</description>
    <arm_group_label>Erlotinib + Pazopanib</arm_group_label>
    <other_name>Votrient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib: 150 mg orally daily</description>
    <arm_group_label>Erlotinib + Pazopanib</arm_group_label>
    <arm_group_label>Erlotinib + Placebo</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologic confirmation of stage IIIB/IV NSCLC (squamous carcinoma, adenocarcinoma, or
             large cell carcinoma) per the American Joint Committee on Cancer Cancer Staging
             Manual, 6th edition. Patients with mixed tumors with small- cell elements are
             ineligible.

          2. At least one lesion that can be accurately measured in at least one dimension (longest
             diameter to be recorded) as &gt;20 mm with conventional techniques, or as &gt;10 mm with
             spiral computerized tomography scan according to the Response Evaluation Criteria in
             Solid Tumors version 1.1 (Eisenhauer et al. 2009)

          3. Failure of at least 1, and no more than 2, prior chemotherapy regimens for advanced
             disease (either due to progressive disease or toxicity).

          4. Recovery from any toxic effects of prior therapy to ≤ grade 1 per the National Cancer
             Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).

          5. Completion of radiation therapy at least 28 days prior to the start of study treatment
             (not including palliative local radiation). Previously irradiated lesions in the
             advanced setting cannot be included as target lesions unless clear tumor progression
             has been observed since the end of radiation.

          6. ECOG Performance Status of 0-2.

          7. Adequate hematologic, hepatic and renal function.

          8. A female is eligible to enter and participate in this study if she is of:

               -  non-childbearing potential (i.e., physiologically incapable of becoming
                  pregnant), including any female who has had hysterectomy, bilateral oophorectomy
                  (ovariectomy), bilateral tubal ligation, is post-menopausal

               -  childbearing potential, including any female who has had a negative serum
                  pregnancy test within 1 week prior to the first dose of study treatment,
                  preferably as close to the first dose as possible, and agrees to use adequate
                  contraception.

          9. Patients entering the study must be willing to provide a serum sample at baseline and
             at off-study for disease progression for correlative serum proteomic testing.

         10. Willingness to provide a plasma sample at baseline, and at off-study for disease
             progression for correlative testing of circulating plasma biomarkers.

         11. Patients entering this study must be willing to provide tissue from a previous tumor
             biopsy (if available) for correlative tissue testing.

         12. Patients must be able to understand the nature of this study, give written informed
             consent, and comply with study requirements.

        Exclusion Criteria:

          1. Past or current history of neoplasm (other than the entry diagnosis), with the
             exception of treated non-melanoma skin cancer or carcinoma in-situ of the cervix, or
             other cancers cured by local therapy alone, and a disease-free survival ≥3 years.

          2. Prior treatment with EGFR tyrosine kinase inhibitors or vascular endothelial factor
             receptor tyrosine kinase inhibitors for NSCLC. [Note: prior bevacizumab (Avastin®) use
             is permitted].

          3. Prior use of an investigational agent within 28 days or 5 half-lives, whichever is
             longer, prior to the first dose of study drug.

          4. History of any one or more of the following cardiovascular conditions within the past
             6 months:

               -  Cardiac angioplasty or stenting

               -  Myocardial infarction

               -  Unstable angina

               -  Coronary artery bypass graft surgery

               -  Symptomatic peripheral vascular disease

               -  Class III or IV congestive heart failure, as defined by New York Heart
                  Association classification

          5. History or clinical evidence of central nervous system (CNS) metastases or
             leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS
             metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure
             medication for 1 week prior to first dose of study drug. Screening with CNS imaging
             (CT or magnetic resonance imaging) is required only if clinically indicated or if the
             subject has a history of CNS metastases.

          6. Women who are pregnant or lactating. All females of childbearing potential must have
             negative serum or urine pregnancy tests within 7 days prior to study treatment.

          7. Poorly controlled hypertension [defined as systolic blood pressure of ≥150 mmHg or
             diastolic blood pressure of ≥90mmHg].

          8. Presence of uncontrolled infection.

          9. Prolongation of heart rate-corrected QT interval (QTc) ≥480 msec (using Bazett's
             formula).

         10. Use of any of the medications on the prohibited medication list within 14 days of
             study treatment (with the exception of Amiodarone, which is prohibited from 6 months
             prior to screening through discontinuation from the study).

         11. A serious underlying medical condition that would impair the ability of the patient to
             receive protocol treatment.

         12. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or
             presence of any non-healing wound, fracture, or ulcer (procedures such as catheter
             placement not considered to be major).

         13. Minor surgical procedures (with the exception of the placement of portacath or other
             central venous access) performed less than 7 days prior to beginning protocol
             treatment.

         14. History of cerebrovascular accident including transient ischemic attack (TIA),
             pulmonary embolism (PE), or untreated DVT within the past 6 months.

         15. Previous treatment with cetuximab.

         16. Patients with hemoptysis or tumor cavitation at baseline.

         17. Any prior history of hypertensive crisis or hypertensive encephalopathy.

         18. Pulmonary hemorrhage/bleeding event within 6 weeks prior to beginning study treatment.

         19. Any other non-pulmonary hemorrhage/bleeding event ≥ grade 3 within 28 days of study
             treatment.

         20. Evidence or history of bleeding diathesis.

         21. Serious non-healing wound, ulcer, or bone fracture.

         22. Known or suspected allergy/hypersensitivity to any agent given in the course of this
             trial.

         23. Clinically significant gastrointestinal (GI) abnormalities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Spigel, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Hem Onc</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates, PA</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology Hematology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Cancer Center</name>
      <address>
        <city>Collerville</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2009</study_first_submitted>
  <study_first_submitted_qc>December 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2009</study_first_posted>
  <results_first_submitted>October 8, 2015</results_first_submitted>
  <results_first_submitted_qc>December 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2016</results_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Previously Treated Advanced Non Small Cell Lung Cancer</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Pazopanib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Erlotinib + Pazopanib</title>
          <description>Erlotinib: 150 mg orally daily
Pazopanib: 600 mg orally daily</description>
        </group>
        <group group_id="P2">
          <title>Erlotinib + Placebo</title>
          <description>Erlotinib: 150 mg orally daily
Placebo: orally daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134">One patient was enrolled but not treated</participants>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Patients remained on treatment until coming off for progression, toxicity or any other reason</participants>
                <participants group_id="P2" count="0">Patients remained on treatment until coming off for progression, toxicity or any other reason</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated patients</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>Erlotinib + Pazopanib
Erlotinib: 150 mg orally daily
Pazopanib: 600 mg orally daily</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>Erlotinib + Placebo
Erlotinib: 150 mg orally daily
Placebo: orally daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="134"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="201"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="35" upper_limit="88"/>
                    <measurement group_id="B2" value="67" lower_limit="48" upper_limit="85"/>
                    <measurement group_id="B3" value="67" lower_limit="35" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Includes all treated patients</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>The length of time, in months, that patients were alive from first date of protocol treatment until worsening of disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>14 months</time_frame>
        <population>All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Erlotinib + Pazopanib
Erlotinib: 150 mg orally daily
Pazopanib: 600 mg orally daily</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Erlotinib + Placebo
Erlotinib: 150 mg orally daily
Placebo: orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>The length of time, in months, that patients were alive from first date of protocol treatment until worsening of disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <population>All treated patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.9" upper_limit="3.2"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.7" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The length of time, in months, that patients were alive from first date of protocol treatment until death.</description>
        <time_frame>18 months</time_frame>
        <population>All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Erlotinib + Pazopanib
Erlotinib: 150 mg orally daily
Pazopanib: 600 mg orally daily</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Erlotinib + Placebo
Erlotinib: 150 mg orally daily
Placebo: orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The length of time, in months, that patients were alive from first date of protocol treatment until death.</description>
          <population>All treated patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.76" lower_limit="4.7" upper_limit="8.1"/>
                    <measurement group_id="O2" value="6.7" lower_limit="5.0" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>The percentage of patients having an objective benefit from treatment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.</description>
        <time_frame>18 Months</time_frame>
        <population>Includes all patients who were evaluated for response</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Erlotinib + Pazopanib
Erlotinib: 150 mg orally daily
Pazopanib: 600 mg orally daily</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Erlotinib + Placebo
Erlotinib: 150 mg orally daily
Placebo: orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>The percentage of patients having an objective benefit from treatment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.</description>
          <population>Includes all patients who were evaluated for response</population>
          <units>percentage of evaluated participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.12"/>
                    <measurement group_id="O2" value="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>Erlotinib + Pazopanib
Erlotinib: 150 mg orally daily
Pazopanib: 600 mg orally daily</description>
        </group>
        <group group_id="E2">
          <title>Arm B</title>
          <description>Erlotinib + Placebo
Erlotinib: 150 mg orally daily
Placebo: orally daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cardiac disorders - Other, tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, hematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, small bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions - Other, disease progression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, Staphylococcus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders - Other, change in mental status</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, COPD exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>General Disorders And Administration Site Conditions - Other, Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections And Infestations - Other, Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>White Blood Cell Decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized Muscle Weakness</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Rash Acneiform</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review/embargo results communications prior to public release for a period that is &gt;60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John D. Hainsworth, MD</name_or_title>
      <organization>Sarah Cannon Research Institute</organization>
      <phone>1-877-691-7274</phone>
      <email>asksarah@scresearch.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

